Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.35 |
| ▸ | MAP3K6 | O95382 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
| ▸ | MDM4 | O15151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL983715 | 0.97 | MCHR1 (0.36) | MCHR1MAP3K5MAP3K6DYRK1AMDM4 | |
| SCHEMBL981769 | 0.96 | MDM4 (0.37) | MCHR1MAP3K5MAP3K6DYRK1AMDM4 | |
| SCHEMBL981811 | 0.93 | PDE4D (0.35) | MCHR1MAP3K5MAP3K6DYRK1AEPHX2 | |
| SCHEMBL985321 | 0.93 | MDM4 (0.37) | MCHR1MAP3K5MAP3K6DYRK1AMDM4 | |
| SCHEMBL985153 | 0.92 | MAP3K5 (0.34) | MCHR1MAP3K5MAP3K6DYRK1AIGF1R | |
| SCHEMBL984207 | 0.92 | MDM4 (0.35) | MCHR1MAP3K5MAP3K6DYRK1AMDM4 | |
| SCHEMBL984985 | 0.92 | MDM4 (0.35) | MCHR1MAP3K5MAP3K6DYRK1AMDM4 | |
| SCHEMBL982064 | 0.91 | MAP3K5 (0.37) | MCHR1MAP3K5MAP3K6DYRK1AMDM4 | |
| SCHEMBL981843 | 0.90 | EPHX2 (0.38) | MCHR1MAP3K5MAP3K6DYRK1AMDM4 | |
| SCHEMBL982596 | 0.90 | MAP3K5 (0.36) | MCHR1MAP3K5MAP3K6DYRK1AMDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-01-27 | — | — | US | claimed |
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | PDE5A, PDE3A, PDE2A | MCHR1 4625/4885MAP3K5 1564/4885MAP3K6 2724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.